Format

Send to

Choose Destination
Br J Cancer. 2017 Jan;116(3):356-361. doi: 10.1038/bjc.2016.427. Epub 2017 Jan 5.

Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival.

Author information

1
Department of Medical Oncology, Centre Léon Bérard, 28 Rue Laennec, Lyon F-69373, France.
2
Direction de la Recherche Clinique et de l'Innovation, Centre Léon Bérard, Lyon F-69373, France.
3
Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, Paris F-95005, France.
4
Department of Medical Oncology, Institut Curie - Hopital René Hugueneau, 35 Rue Dailly, Saint Cloud F-92210, France.
5
INSERM, UMR-S 1036, Grenoble F-38054, France.
6
University Grenoble-Alpes, Grenoble F-38000, France.
7
CEA, DRF, Biosciences and Biotechnology Institute of Grenoble (BIG), Laboratory of Biology of Cancer and Infection, Grenoble F-38054, France.

Abstract

BACKGROUND:

Patients with metastatic breast cancer (MBC) represent a heterogeneous group, with large differences in outcomes from individual patients. VE-cadherin, an endothelial-specific cadherin, was shown to promote tumour proliferation and angiogenesis. Soluble VE-cadherin has been recently associated to breast cancer progression. This study was designed to investigate the prognosis significance of soluble VE-cadherin in hormone-refractory MBC.

METHODS:

Between 2004 and 2007, 150 patients with a fully documented history of hormone-refractory MBC were included in the prospective SEMTOF study. Serum concentrations of VE-cadherin were measured at inclusion for 141 patients and 6 weeks after the beginning of chemotherapy, using a sandwich enzyme immunoassay.

RESULTS:

The presence of high levels of serum VE-cadherin was significantly correlated to a shorter progression-free (PFS) and overall survival (OS). In a multivariate analysis along with clinical and biologic prognostic parameters, high serum VE-cadherin level was an independent adverse prognostic variable for PFS (median PFS 9.7 (IC95: 8; 11.9) vs 5.8 (IC95: 4.1; 8) months P=0.0008) and OS (median OS 34 (IC95: 26.6; 47.1) vs 14.8 (IC95: 9.3; 21.4) months P=0.0007). Moreover, VE-cadherin decrease during chemotherapy was also associated with good prognosis.

CONCLUSIONS:

Serum VE-cadherin levels correlate to poorer survival in patients with hormone-refractory MBC. As sVE-cadherin reflects tumour angiogenesis, this could have therapeutic implications for antiangiogenic treatment.

PMID:
28056463
PMCID:
PMC5294483
DOI:
10.1038/bjc.2016.427
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center